Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer's Disease Landscape

Bougea A., Debasa-Mouce M., Gulkarov S., Castro-Mosquera M., Reiss AB., Ouro A.

Narrative Review on Neuroinflammation, published in Medicina (Kaunas) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Medicina (Kaunas) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40870510
PMCID
PMC12388077
DOI
10.3390/medicina61081462
Citations
1

Abstract (original English)

Background and Objectives : Over the past few years, there has been a significant shift in focus from developing better diagnostic tools to detecting Alzheimer's disease (AD) earlier and initiating treatment interventions. This review will explore four main objectives: (a) the role of biomarkers in enhancing the diagnostic accuracy of AD, highlighting the major strides that have been made in recent years; (b) the role of neuropsychological testing in identifying biomarkers of AD, including the relationship between cognitive performance and neuroimaging biomarkers; (c) the amyloid hypothesis and possible molecular mechanisms of AD; and (d) the innovative AD therapeutics and the challenges and limitations of AD research. Materials and Methods : We have searched PubMed and Scopus databases for peer-reviewed research articles published in English (preclinical and clinical studies as well as relevant reviews and meta-analyses) investigating the molecular mechanisms, biomarkers, and treatments of AD. Results : Genome-wide association studies (GWASs) discovered 37 loci associated with AD risk. Core 1 biomarkers (α-amyloid Aβ42, phosphorylated tau, and amyloid PET) detect early AD phases, identifying both symptomatic and asymptomatic individuals, while core 2 biomarkers inform the short-term progression risk in individuals without symptoms. The recurrent failures of Aβ-targeted clinica

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAlzheimer Diseasetau ProteinsEarly DiagnosisNeuropsychological TestsGenome-Wide Association StudyAmyloid beta-PeptidesBiomarkers

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research